Relapsed/Refractory Mantle Cell Lymphoma Clinical Trial
Official title:
A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
In this trial, patients with mantle cell lymphoma will be included, treatment with
lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12
cycles, cycle length 28 days. Patients with complete remission, partial response or stable
disease will enter a maintenance phase with treatment with ibrutinib and rituximab until
progression of disease.
The primary objective is to evaluate overall response rate, based on PET and CT.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02601313 -
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
|
Phase 2 | |
| Recruiting |
NCT06253663 -
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Completed |
NCT01838434 -
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
|
Phase 1 | |
| Completed |
NCT03886831 -
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04880434 -
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
|
Phase 2 |